The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Open accessAbstract
In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining β-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual β-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: ≤0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (∼65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of ∼30%. Therefore, even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”
From Type 1 diabetes (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding is noteworthy because in the Diabetes Control and Complications Trial68,69 persistent C-peptide secretion was associated with reduced development of retinopathy, nephropathy, and hypoglycaemia.”
From Type 1 diabetes (2018) · cites this paper as [69]
In the citing paper
“In addition, we analysed two other thresholds: UCPCR≥0.03 nmol/mmol and ≥0.2nmol/mmol, which are equivalent to serum C peptide of 30 pmol/L (a common historical limit of detection(3; 11; 12)) and 200 pmol/L (a clinically defined level associated with reduced microvascular complications and hypoglycaemia(13)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
The DCCT Research Group (1986) · Diabetes · doi:10.2337/diabetes.35.5.530 · Cited by 466
(1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100010038019 · Cited by 325
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 215
Cited by
Sorted by citations
Items 101–200 of 697
Gerber, P. A., Pavlicek, V., Demartines, N., Zuellig, R. A., Pfammatter, T., Wuthrich, R. P., Weber, M., Spinas, G. A., & Lehmann, R. (2007) · Diabetologia · doi:10.1007/s00125-007-0860-4 · Cited by 94
Preservation of β-cell function in autoantibody-positive youth with diabetes
Greenbaum, C. J., Anderson, A. M., Dolan, L. M., Mayer-Davis, E. J., Dabelea, D., Imperatore, G., Marcovina, S., Pihoker, C., & for the SEARCH Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2326 · Cited by 90
Marques, R. G., Fontaine, M. J., & Rogers, J. D. (2004) · Pancreas · doi:10.1097/00006676-200410000-00009 · Cited by 90
Sørensen, J., Johannesen, J., Pociot, F., Kristensen, K., Thomsen, J. F., Hertel, N. T., Kjærsgaard, P., Brorsson, C., Birkebæk, N., & the Danish Society for Diabetes in Childhood and Adolescence (2013) · Diabetes Care · doi:10.2337/dc13-0418 · Cited by 90
Luppi, P., Cifarelli, V., Tse, H. M., Piganelli, J. D., & Trucco, M. (2008) · Diabetologia · doi:10.1007/s00125-008-1032-x · Cited by 89
MCVEAN, J. J. F., Forlenza, G. P., Beck, R. W., Bauza, C., Bailey, R. J., Buckingham, B. A., DiMeglio, L. A., Sherr, J. L., Clements, M., Neyman, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.2063 · Cited by 90
Gubitosi-Klug, R. A., Braffett, B. H., Hitt, S., Arends, V., Uschner, D., Jones, K., Diminick, L., Karger, A. B., Paterson, A. D., Roshandel, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143011 · Cited by 86
Self-citationC-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy
Bhatt, M. P., Lim, Y.-C., & Ha, K. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu211 · Cited by 86
Bo, S., Gentile, L., Castiglione, A., Prandi, V., Canil, S., Ghigo, E., & Ciccone, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0085 · Cited by 85
Besser, R. E. J., Ludvigsson, J., Jones, A. G., McDonald, T. J., Shields, B. M., Knight, B. A., & Hattersley, A. T. (2011) · Diabetes Care · doi:10.2337/dc10-2114 · Cited by 82
Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers
Fonolleda, M., Murillo, M., Vázquez, F., Bel, J., & Vives‐Pi, M. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479030 · Cited by 81
Immunotherapy for the Prevention and Treatment of Type 1 Diabetes
Rewers, M., & Gottlieb, P. A. (2009) · Diabetes Care · doi:10.2337/dc09-0374 · Cited by 80
Ludvigsson, J., Hjorth, M., Chéramy, M., Axelsson, S., Pihl, M., Forsander, G., Nilsson, N.-O., Samuelsson, B.-O., Wood, T., Åman, J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1988-1 · Cited by 79
Phases of type 1 diabetes in children and adolescents
Couper, J., Haller, M. J., Ziegler, A., Knip, M., Ludvigsson, J., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12188 · Cited by 81
Addressing insulin resistance in Type 1 diabetes
Pang, T. T. L., & Narendran, P. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02493.x · Cited by 81
Dabelea, D., Mayer-Davis, E. J., Andrews, J. S., Dolan, L. M., Pihoker, C., Hamman, R. F., Greenbaum, C., Marcovina, S., Fujimoto, W., Linder, B., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2719-6 · Cited by 76
Berney, T., Ferrari‐Lacraz, S., Bühler, L. H., Oberholzer, J., Marangon, N., Philippé, J., Villard, J., & Morel, P. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02481.x · Cited by 78
C-peptide in the classification of diabetes in children and adolescents
Ludvigsson, J., Carlsson, A., Forsander, G., Ivarsson, S. A., Kockum, I. S., Lernmark, Å., Lindblad, B., Marcus, C., & Samuelsson, U. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00807.x · Cited by 74
Ludvigsson, J., Carlsson, A., Deli, A., Forsander, G., Ivarsson, S. A., Kockum, I. S., Lindblad, B., Marcus, C., Lernmark, Å., & Samuelsson, U. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.003 · Cited by 75
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1506 · Cited by 75
Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy
Liu, M., & Han, Z. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00288.x · Cited by 74
Lynam, A., McDonald, T., Hill, A., Dennis, J., Oram, R., Pearson, E., Weedon, M., Hattersley, A., Owen, K., Shields, B., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031586 · Cited by 72
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
Jacobsen, L. M., Bundy, B. N., Greco, M. N., Schatz, D., Atkinson, M. A., Brusko, T. M., Mathews, C. E., Herold, K. C., Gitelman, S. E., Krischer, J. P., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0305 · Cited by 71
Heikkilä, E., Hermant, A., Thévenet, J., Bermont, F., Kulkarni, S. S., Ratajczak, J., Domingo, J. S., Dioum, E. M., Cantó, C., Barron, D., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14757 · Cited by 71
Continuous Glucose Monitoring Predicts Progression to Diabetes in Autoantibody Positive Children
Steck, A. K., Dong, F., Taki, I., Hoffman, M., Simmons, K. M., Frohnert, B. I., & Rewers, M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02196 · Cited by 71
Maddaloni, E., Coleman, R. L., Agbaje, O. F., Buzzetti, R., & Holman, R. R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30003-6 · Cited by 74
on behalf of the FinnDiane Study Group, Hietala, K., Wadén, J., Forsblom, C. M., Harjutsalo, V., Kytö, J., Summanen, P. A., & Groop, P. (2013) · Diabetologia · doi:10.1007/s00125-012-2816-6 · Cited by 70
Kawada-Horitani, E., Kita, S., Okita, T., Nakamura, Y., Nishida, H., Honma, Y., Fukuda, S., Tsugawa-Shimizu, Y., Kozawa, J., Sakaue, T., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05708-3 · Cited by 69
Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
Buckingham, B. A., Beck, R. W., Ruedy, K. J., Cheng, P., Kollman, C., WEINZIMER, S. A., DiMeglio, L. A., Bremer, A. A., Slover, R., & Tamborlane, W. V. (2013) · Diabetes Care · doi:10.2337/dc13-1074 · Cited by 69
Kim, B., Jung, C., Mok, J., Kang, S., & Kim, C. (2011) · Acta Diabetologica · doi:10.1007/s00592-010-0249-6 · Cited by 69
The broad clinical phenotype of Type 1 diabetes at presentation
Merger, S. R., Leslie, R. D., & Boehm, B. O. (2012) · Diabetic Medicine · doi:10.1111/dme.12048 · Cited by 71
Carnevale, G., Riccio, M., Pisciotta, A., Beretti, F., Maraldi, T., Zavatti, M., Cavallini, G. M., Sala, G. B. L., Ferrari, A., & Pol, A. D. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.02.007 · Cited by 69
Aschner, P. J., Horton, E., Leiter, L. A., Munro, N. M., Skyler, J. S., & Management*, O. B. O. T. G. P. F. E. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02296.x · Cited by 69
Thunander, M., Thorgeirsson, H., Törn, C., Petersson, C., & Landin‐Olsson, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0901 · Cited by 68
Cifarelli, V., Luppi, P., Tse, H. M., He, J., Piganelli, J. D., & Trucco, M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.12.060 · Cited by 69
Pathogenesis of type 1 diabetes: lessons from natural history studies of high‐risk individuals
Nokoff, N., & Rewers, M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12021 · Cited by 71
Precision medicine in type 1 diabetes
Carr, A. L. J., Evans‐Molina, C., & Oram, R. A. (2022) · Diabetologia · doi:10.1007/s00125-022-05778-3 · Cited by 69
Gibb, F. W., McKnight, J. A., Clarke, C., & Strachan, M. W. J. (2020) · Diabetologia · doi:10.1007/s00125-020-05099-3 · Cited by 72
Temporary Preservation of β-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes
Örtqvist, E., Björk, E., Wallensteen, M., Ludvigsson, J., Åman, J., Johansson, C., Forsander, G., Lindgren, F., Berglund, L., Bengtsson, M., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2191 · Cited by 64
Buzzetti, R., Pozzilli, P., Frederich, R. C., Iqbal, N., & Hirshberg, B. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2717 · Cited by 64
Maffi, P., Scavini, M., Socci, C., Piemonti, L., Caldara, R., Gremizzi, C., Melzi, R., Nano, R., Orsenigo, E., Venturini, M., et al. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.44 · Cited by 65
Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2
Dwyer, C. J., Ward, N. C., Pugliese, A., & Malek, T. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0739-1 · Cited by 65
Hedman, C. A., Frystyk, J., Lindström, T., Chen, J., Flyvbjerg, A., Ørskov, H., & Arnqvist, H. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0572 · Cited by 63
Enhanced insulin sensitivity in skeletal muscle and liver by physiological overexpression of SIRT6
Anderson, J. G., Ramadori, G., Ioris, R. M., Galiè, M., Berglund, E. D., Coate, K. C., Fujikawa, T., Pucciarelli, S., Moreschini, B., Amici, A. R. D., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.003 · Cited by 62
Peptide Immunotherapy for Type 1 Diabetes—Clinical Advances
Smith, E., & Peakman, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00392 · Cited by 62
Knobler, R., Arenberger, P., Arun, A., Assaf, C., Bagot, M., Berlin, G., Bohbot, A., Calzavara‐Pinton, P., Child, F. J., Cho, A., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16889 · Cited by 63
Delli, A. J., Larsson, H. E., Ivarsson, S. A., & Lernmark, Å. (2010) · Wiley eBooks · doi:10.1002/9781444324808 · Cited by 69
C‐peptide in the natural history of type 1 diabetes
Palmer, J. P. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.943 · Cited by 62
Carlsson, P., Espes, D., Sisay, S., Davies, L. C., Rjh, S., & Svahn, M. G. (2023) · Diabetologia · doi:10.1007/s00125-023-05934-3 · Cited by 60
Sosenko, J. M., Palmer, J. P., Greenbaum, C. J., Mahon, J. L., Cowie, C. C., Krischer, J. P., Chase, H. P., White, N. H., Buckingham, B. A., Herold, K. C., et al. (2006) · Diabetes Care · doi:10.2337/dc06-1615 · Cited by 60
C‐peptide: new findings and therapeutic implications in diabetes
Wahren, J. (2004) · Clinical Physiology and Functional Imaging · doi:10.1111/j.1475-097x.2004.00558.x · Cited by 60
Thunander, M., Törn, C., Petersson, C., Ossiansson, B., Fornander, J., & Landin‐Olsson, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0797 · Cited by 60
Lehmann, R., Weber, M., Berthold, P., Züllig, R., Pfammatter, T., Moritz, W., Mädler, K., Donath, M. Y., Ambühl, P. M., Demartines, N., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00468.x · Cited by 59
Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 59
Niedźwiecki, P., Piłaciński, S., Uruska, A. A., Adamska, A., Naskręt, D., & Zozulińska‐Ziółkiewicz, D. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.002 · Cited by 57
Raz, I., Ziegler, A. G., Linn, T., Schernthaner, G., Bonńici, F., Distiller, L. A., Giordano, C. S. D. S., Giorgino, F., de Vries, L., Mauricio, D., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1391 · Cited by 57
RetractedTriolo, T. M., Chase, H. P., Barker, J. M., & the DPT-1 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1872 · Cited by 57
Steck, A. K., Larsson, H. E., Liu, X., Veijola, R., Toppari, J., Hagopian, W. A., Haller, M. J., Ahmed, S., Akolkar, B., Lernmark, Å., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12485 · Cited by 56
Liu, E. H., Digon, B. J., Hirshberg, B., Chang, R., Wood, B. J., Neeman, Z., Kam, A. W., WESLEY, R. A., Polly, S. M., Hofmann, R. M., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1342-7 · Cited by 57
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U. L., Holst, J. J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
Sosenko, J. M., Skyler, J. S., Herold, K. C., Palmer, J. P., & Groups, T. T. 1. D. T. A. D. P. T. 1. S. (2012) · Diabetes · doi:10.2337/db11-1660 · Cited by 58
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Greenbaum, C. J., VanBuecken, D., & Lord, S. M. (2019) · Drugs · doi:10.1007/s40265-018-1035-y · Cited by 56
Svensson, J., Sildorf, S. M., Pipper, C. B., Kyvsgaard, J. N., Bøjstrup, J., Pociot, F., Mortensen, H. B., & Buschard, K. (2016) · SpringerPlus · doi:10.1186/s40064-016-2641-3 · Cited by 53
Schölin, A., Björklund, L., Borg, H., Arnqvist, H. J., Björk, E., Blohmé, G., Bolinder, J., Eriksson, J. W., Guðbjörnsdóttir, S., Nyström, L., et al. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01273.x · Cited by 53
A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes
Marino, K. R., Lundberg, R. L., Jasrotia, A., Maranda, L., Thompson, M. J., BARTON, B. A., Alonso, L. C., & Nwosu, B. U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176860 · Cited by 52
Narendran, P., Jackson, N., Daley, A., Thompson, D., Stokes, K., Greenfield, S., Charlton, M., Curran, M., Solomon, T. P. J., Nouwen, A., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13439 · Cited by 52
The Epidemiology of Diabetic Retinopathy
Klein, R. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-563-3_3 · Cited by 51
Birkebæk, N., Drivvoll, A., Aakesson, K., Bjarnason, R. G., Johansen, A., Samuelsson, U., Skrivarhaug, T., Þórsson, Á. V., & Svensson, J. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000377 · Cited by 51
Luan, F. L., Miles, C. D., Cibrik, D. M., & OJO, A. O. (2007) · Transplantation · doi:10.1097/01.tp.0000270617.43811.af · Cited by 51
Steck, A. K., Dong, F., Taki, I., Hoffman, M., KLINGENSMITH, G. J., & Rewers, M. (2014) · Diabetes Care · doi:10.2337/dc13-2965 · Cited by 50
Li, L., Hui, H., Jia, X., Zhang, J., Liu, Y. M., Xu, Q., & Zhu, D. (2016) · Scientific Reports · doi:10.1038/srep37894 · Cited by 50
Recovery of endocrine function after islet and pancreas transplantation
Rickels, M. R. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0294-3 · Cited by 49
Potential role of non‐insulin adjunct therapy in Type 1 diabetes
George, P., & McCrimmon, R. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03744.x · Cited by 49
Battaglia, M., & Roncarolo, M. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.007 · Cited by 50
Distinct Roles of β-Cell Mass and Function During Type 1 Diabetes Onset and Remission
Chmelova, H., Cohrs, C. M., Chouinard, J. A., Petzold, C., Kühn, M., Chen, C., Roeder, I., Kretschmer, K., & Speier, S. (2015) · Diabetes · doi:10.2337/db14-1055 · Cited by 50
Murase, Y., Imagawa, A., Hanafusa, T., Iwahashi, H., Uchigata, Y., Kanatsuka, A., Kawasaki, E., Kobayashi, T., Shimada, A., Shimizu, I., et al. (2007) · Diabetologia · doi:10.1007/s00125-006-0575-y · Cited by 49
Buckingham, B. A., Cheng, P., Beck, R. W., Kollman, C., Ruedy, K. J., WEINZIMER, S. A., Slover, R. H., Bremer, A. A., Fuqua, J. S., & Tamborlane, W. V. (2015) · Diabetologia · doi:10.1007/s00125-015-3559-y · Cited by 48
Brooks, A. M., Oram, R. A., Home, P., Steen, N., & Shaw, J. (2014) · Diabetes Care · doi:10.2337/dc14-1656 · Cited by 49
Ludvigsson, J. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.941 · Cited by 48
100 YEARS OF INSULIN: Pancreas pathology in type 1 diabetes: an evolving story
Richardson, S. J., & Pugliese, A. (2021) · Journal of Endocrinology · doi:10.1530/joe-21-0358 · Cited by 48
Prevention of type 1 diabetes: the time has come
Sherr, J. L., Sosenko, J. M., Skyler, J. S., & Herold, K. C. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0832 · Cited by 47
Immune intervention in type 1 diabetes
Michels, A. W., & Eisenbarth, G. S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.003 · Cited by 47
Pecheur, A., Barrea, T., Vandooren, V., Beauloye, V., Robert, A. R., & Lysy, P. A. (2014) · Journal of Diabetes Research · doi:10.1155/2014/851378 · Cited by 47
Sharma, S. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/27321.10645 · Cited by 46
Nutritional Factors and Preservation of C-Peptide in Youth With Recently Diagnosed Type 1 Diabetes
Mayer‐Davis, E. J., Dabelea, D., Crandell, J., Crume, T., D’Agostino, R. B., Dolan, L. M., King, I. B., Lawrence, J. M., Norris, J. M., Pihoker, C., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2084 · Cited by 45
Lu, J., Hou, X., Zhang, L., Jiang, F., Hu, C., Bao, Y., & Jia, W. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0711-y · Cited by 45
DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes
Roshandel, D., Chen, Z., Canty, A. J., Bull, S. B., Natarajan, R. D., & Paterson, A. D. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00840-6 · Cited by 48
Determinants of glucose control in patients with chronic pancreatitis
Schrader, H., Menge, B., Zeidler, C., Ritter, P. R., Tannapfel, A., Uhl, W. H., Schmidt, W. E., & Meier, J. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1705-0 · Cited by 45
Effect of Ingested Interferon-α on β-Cell Function in Children With New-Onset Type 1 Diabetes
Rother, K. I., Brown, R. J., Morales, M. M., Wright, E. C., Duan, Z., Campbell, C., Hardin, D. S., Popovic, J., McEvoy, R. C., Harlan, D. M., et al. (2009) · Diabetes Care · doi:10.2337/dc08-2029 · Cited by 45
Sosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Beam, C. A., Boulware, D. C., Greenbaum, C. J., Rafkin, L. E., Cowie, C., Cuthbertson, D., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0011 · Cited by 44
Rydén, A. K., Perdue, N., Pagni, P. P., Gibson, C. B., Ratliff, S. S., Kirk, R. K., Friesen, T. J., Haase, C., Coppieters, K. T., von Herrath, M. G., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.006 · Cited by 44
Nakanishi, K., & Watanabe, C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1209 · Cited by 45
Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
Greenbaum, C. J., Schatz, D., Haller, M. J., & Sanda, S. (2012) · Diabetes · doi:10.2337/db11-1452 · Cited by 46
GLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 43
Hope, S. V., Knight, B., Shields, B. M., Hill, A. V., Choudhary, P., Strain, W. D., McDonald, T. J., & Jones, A. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4449-2 · Cited by 47
Antigen-Specific Therapeutic Approaches in Type 1 DiabetesPreprint
Clemente‐Casares, X., Tsai, S. J., Huang, C., & Santamaría, P. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007773 · Cited by 46
Ludvigsson, J., Chéramy, M., Axelsson, S., Pihl, M., Åkerman, L., Casas, R., & for the clinical GAD‐study group in Sweden (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2503 · Cited by 42
International Comparison of C-Peptide Measurements
Wiedmeyer, H.-M., Polonsky, K. S., Myers, G. L., Little, R. R., Greenbaum, C. J., Goldstein, D. E., & Palmer, J. P. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081570 · Cited by 42
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42
Ludvigsson, J. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.02.006 · Cited by 42
Metadata
- Authors
- Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W.
- Affiliations
- University of Minnesota (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 832-836
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988519907
- Cited by
- 695
- References
- 25
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 39 · 2021: 49 · 2020: 38 · 2019: 29 · 2018: 31 · 2017: 32 · 2016: 30 · 2015: 44 · 2014: 32 · 2013: 53 · 2012: 37
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000400, M01-RR00400)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, residual beta-cell function, C-peptide, diabetic retinopathy, diabetic nephropathy, albuminuria, severe hypoglycemia, intensive insulin therapy, diabetes complications, Diabetes Control and Complications Trial
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Islets of Langerhans, Male, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
